Michael Barbella, Managing Editor06.01.23
Cardio Diagnostics Holdings Inc. has entered into a strategic engagement with Lifespan.io to enhance public awareness and create comprehensive educational resources for heart disease prevention and longevity.
“Engaging with Lifespan.io marks a significant step forward in our commitment to partner with forward-thinking organizations in the longevity space," Cardio Diagnostics Chief Medical Officer Robert Philibert, M.D., Ph.D., said. "Cardiovascular disease is inextricably linked with aging, and enhancing cardiovascular health outcomes and extending life go hand in hand. By pooling our expertise and resources, we can effectively educate individuals on the importance of heart health and empower them to take practical steps toward living longer, healthier lives by introducing epigenetics and the link to heart disease.”
The strategic education engagement will encompass attendance at Lifespan.io’s conference, sponsored research articles, and journal article reviews that tackle key aspects of heart disease prevention, including the roles of epigenetics, genetics, lifestyle factors, and innovative diagnostic tools driven by artificial intelligence. By elevating public awareness and understanding of cardiovascular health and longevity, Cardio Diagnostics and Lifespan.io aim to motivate individuals to proactively maintain their heart health and adopt practices that facilitate longer healthier lives.
The organizations plan to build out additional collaborative efforts on future projects and initiatives aimed at generating awareness for and advancing cardiovascular health and longevity biotechnology research. This summer, Cardio Diagnostics will attend Lifespan.io’s Longevity and DeSci Summit: Ending Age-Related Diseases 2023 in New York City (Aug. 10-11).
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention and early detection more accessible, personalized, and precise. The company was formed to further develop and commercialize clinical tests by leveraging a proprietary artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine for cardiovascular disease to become a leading medical technology company for enabling improved prevention, early detection, and assistance in treating cardiovascular disease.
Lifespan.io is a 501(c)(3) nonprofit advocacy foundation and online platform committed to advancing the science of aging and promoting healthy human lifespan. By supporting research projects, disseminating educational resources, and raising public awareness about the importance of longevity, Lifespan.io aims to accelerate the development of therapies that can improve the quality of life for people worldwide. It is a nonprofit news and educational resource for longevity biotechnology and aging research. Among other high-impact channels, Lifespan.io operates a multi-million-subscriber Youtube channel, Life Noggin, which translates science in an engaging and accessible manner despite tackling complex and emerging sciences and technologies that impact aging.
“Engaging with Lifespan.io marks a significant step forward in our commitment to partner with forward-thinking organizations in the longevity space," Cardio Diagnostics Chief Medical Officer Robert Philibert, M.D., Ph.D., said. "Cardiovascular disease is inextricably linked with aging, and enhancing cardiovascular health outcomes and extending life go hand in hand. By pooling our expertise and resources, we can effectively educate individuals on the importance of heart health and empower them to take practical steps toward living longer, healthier lives by introducing epigenetics and the link to heart disease.”
The strategic education engagement will encompass attendance at Lifespan.io’s conference, sponsored research articles, and journal article reviews that tackle key aspects of heart disease prevention, including the roles of epigenetics, genetics, lifestyle factors, and innovative diagnostic tools driven by artificial intelligence. By elevating public awareness and understanding of cardiovascular health and longevity, Cardio Diagnostics and Lifespan.io aim to motivate individuals to proactively maintain their heart health and adopt practices that facilitate longer healthier lives.
The organizations plan to build out additional collaborative efforts on future projects and initiatives aimed at generating awareness for and advancing cardiovascular health and longevity biotechnology research. This summer, Cardio Diagnostics will attend Lifespan.io’s Longevity and DeSci Summit: Ending Age-Related Diseases 2023 in New York City (Aug. 10-11).
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention and early detection more accessible, personalized, and precise. The company was formed to further develop and commercialize clinical tests by leveraging a proprietary artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine for cardiovascular disease to become a leading medical technology company for enabling improved prevention, early detection, and assistance in treating cardiovascular disease.
Lifespan.io is a 501(c)(3) nonprofit advocacy foundation and online platform committed to advancing the science of aging and promoting healthy human lifespan. By supporting research projects, disseminating educational resources, and raising public awareness about the importance of longevity, Lifespan.io aims to accelerate the development of therapies that can improve the quality of life for people worldwide. It is a nonprofit news and educational resource for longevity biotechnology and aging research. Among other high-impact channels, Lifespan.io operates a multi-million-subscriber Youtube channel, Life Noggin, which translates science in an engaging and accessible manner despite tackling complex and emerging sciences and technologies that impact aging.